<div id="readability-page-1"><div><p>Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2025. These A Shares will be under lockup for 1837 days starting from 10-SEP-2020 to 21-SEP-2025.</p><p>  Details:<br/> The company shareholders, namely, Ningbo Zhongjin Guolian Xinde Equity Investment Partnership (Limited Partnership), Wuxi Hongshi Huiquan Equity Investment Management Center (Limited Partnership), Qiu Weihong, issuer directors, Chu Yizhou and Liu Meihua, issuer's director and general manager Chu Dingjun have agreed not to dispose of their interest for a period of 12 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect.</p><p>  The company controlling shareholders, namely, Zhejiang Tongben Investment Co., Ltd., Tiantai Platinum Investment Partnership (Limited Partnership), chairman and actual controller, namely, Peng Zhien, Director Qiu Peijing, Li Jianwen, Chairman of the Board of Supervisors Jin Ping, senior manager of the issuer, Xin Mingyan, Chen Jieming, Zhang Liqin, Wang Xiuyu, Li Fangfang, employee supervisor Yang Liwei have agreed not to dispose of their interest for a period of 36 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect.</p><p>The controlling shareholder, namely, Tiantai Platinum Investment Management Partnership (Limited Partnership), and deputy general manager of the issuer, Wang Guoping have agreed not to dispose of their interest for a period of 60 months from the date of listing. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect.</p></div></div>

奥锐特

<p>奥锐特制药有限公司的部分 A 股在锁定协议下，直到 2025 年 9 月 21 日，锁定期为 1837 天，自 2020 年 9 月 10 日起计算。包括宁波中金国联和无锡鸿石汇泉在内的股东在上市后 12 个月内不得处置其股份，具体情况可能根据股价表现进行延长。控股股东面临 36 个月的锁定期，而另一组股东则有 60 个月的限制。锁定期结束后，年度股份转让限制为持股的 25%</p>

奥锐特制药股份有限公司的部分 A 股受到锁定协议的限制，该协议将于2025年9月21日到期